Biotech investors are still stunned by the rise and fall of the one-drop blood testing startup. But they’re hellbent on making sure they don’t all get burned again. https://media.wired.com/photos/5980fe2e5a15241e571a369b/master/pass/TheranosHP_14754916.jpg Feed: All Latest
